vs
渤健（BIIB）与先锋自然资源公司（PR）财务数据对比。点击上方公司名可切换其他公司
渤健的季度营收约是先锋自然资源公司的1.9倍（$2.3B vs $1.2B），先锋自然资源公司净利率更高（29.0% vs -2.1%，领先31.2%），渤健同比增速更快（-7.1% vs -9.8%），过去两年渤健的营收复合增速更高（-0.2% vs -3.0%）
渤健是总部位于美国马萨诸塞州剑桥市的跨国生物技术企业，专注于神经系统疾病治疗领域。公司核心产品包括用于多发性硬化症的特菲达、万立能等多款药物，以及治疗脊髓性肌萎缩症的诺西那生钠、治疗弗里德赖希共济失调的Skyclarys，致力于为神经疾病和罕见病患者提供创新疗法。
先锋自然资源公司总部位于美国得克萨斯州欧文市，主要从事油气勘探业务，运营覆盖二叠纪盆地Spraberry产区的克莱恩页岩区块，是该区域最大的土地权益持有方，2024年5月被埃克森美孚收购。
BIIB vs PR — 直观对比
营收规模更大
BIIB
是对方的1.9倍
$1.2B
营收增速更快
BIIB
高出2.6%
-9.8%
净利率更高
PR
高出31.2%
-2.1%
两年增速更快
BIIB
近两年复合增速
-3.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $2.3B | $1.2B |
| 净利润 | $-48.9M | $339.5M |
| 毛利率 | 78.3% | — |
| 营业利润率 | -2.5% | 23.1% |
| 净利率 | -2.1% | 29.0% |
| 营收同比 | -7.1% | -9.8% |
| 净利润同比 | -118.3% | 56.7% |
| 每股收益（稀释后） | $-0.35 | $0.48 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BIIBPR
| Q4 25 | $2.3B | $1.2B | ||
| Q3 25 | $2.5B | $1.3B | ||
| Q2 25 | $2.6B | $1.2B | ||
| Q1 25 | $2.4B | $1.4B | ||
| Q4 24 | $2.5B | $1.3B | ||
| Q3 24 | $2.5B | $1.2B | ||
| Q2 24 | $2.5B | $1.2B | ||
| Q1 24 | $2.3B | $1.2B |
净利润BIIBPR
| Q4 25 | $-48.9M | $339.5M | ||
| Q3 25 | $466.5M | $59.2M | ||
| Q2 25 | $634.8M | $207.1M | ||
| Q1 25 | $240.5M | $329.3M | ||
| Q4 24 | $266.7M | $216.7M | ||
| Q3 24 | $388.5M | $386.4M | ||
| Q2 24 | $583.6M | $235.1M | ||
| Q1 24 | $393.4M | $146.6M |
毛利率BIIBPR
| Q4 25 | 78.3% | — | ||
| Q3 25 | 73.4% | — | ||
| Q2 25 | 77.1% | — | ||
| Q1 25 | 74.1% | — | ||
| Q4 24 | 76.2% | — | ||
| Q3 24 | 74.1% | — | ||
| Q2 24 | 77.8% | — | ||
| Q1 24 | 76.3% | — |
营业利润率BIIBPR
| Q4 25 | -2.5% | 23.1% | ||
| Q3 25 | 22.0% | 29.6% | ||
| Q2 25 | 28.1% | 24.8% | ||
| Q1 25 | 12.8% | 36.6% | ||
| Q4 24 | 11.9% | 32.8% | ||
| Q3 24 | 18.3% | 32.5% | ||
| Q2 24 | 28.3% | 36.5% | ||
| Q1 24 | 20.3% | 37.7% |
净利率BIIBPR
| Q4 25 | -2.1% | 29.0% | ||
| Q3 25 | 18.4% | 4.5% | ||
| Q2 25 | 24.0% | 17.3% | ||
| Q1 25 | 9.9% | 23.9% | ||
| Q4 24 | 10.9% | 16.7% | ||
| Q3 24 | 15.8% | 31.8% | ||
| Q2 24 | 23.7% | 18.9% | ||
| Q1 24 | 17.2% | 11.8% |
每股收益（稀释后）BIIBPR
| Q4 25 | $-0.35 | $0.48 | ||
| Q3 25 | $3.17 | $0.08 | ||
| Q2 25 | $4.33 | $0.28 | ||
| Q1 25 | $1.64 | $0.44 | ||
| Q4 24 | $1.82 | $0.31 | ||
| Q3 24 | $2.66 | $0.53 | ||
| Q2 24 | $4.00 | $0.36 | ||
| Q1 24 | $2.70 | $0.25 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $153.7M |
| 总债务越低越好 | $6.3B | $3.5B |
| 股东权益账面价值 | $18.3B | $10.3B |
| 总资产 | $29.4B | $17.9B |
| 负债/权益比越低杠杆越低 | 0.34× | 0.34× |
8季度趋势，按日历期对齐
现金及短期投资BIIBPR
| Q4 25 | — | $153.7M | ||
| Q3 25 | — | $111.8M | ||
| Q2 25 | — | $451.0M | ||
| Q1 25 | — | $702.2M | ||
| Q4 24 | — | $479.3M | ||
| Q3 24 | — | $272.0M | ||
| Q2 24 | — | $47.8M | ||
| Q1 24 | — | $12.7M |
总债务BIIBPR
| Q4 25 | $6.3B | $3.5B | ||
| Q3 25 | $6.3B | $3.5B | ||
| Q2 25 | $6.3B | $4.0B | ||
| Q1 25 | $4.5B | $4.0B | ||
| Q4 24 | $6.3B | $4.2B | ||
| Q3 24 | $4.5B | $4.2B | ||
| Q2 24 | $6.3B | $3.9B | ||
| Q1 24 | $6.3B | $3.9B |
股东权益BIIBPR
| Q4 25 | $18.3B | $10.3B | ||
| Q3 25 | $18.2B | $10.0B | ||
| Q2 25 | $17.6B | $9.5B | ||
| Q1 25 | $17.0B | $9.4B | ||
| Q4 24 | $16.7B | $9.1B | ||
| Q3 24 | $16.4B | $9.0B | ||
| Q2 24 | $15.9B | $8.3B | ||
| Q1 24 | $15.2B | $7.0B |
总资产BIIBPR
| Q4 25 | $29.4B | $17.9B | ||
| Q3 25 | $29.2B | $17.3B | ||
| Q2 25 | $28.3B | $17.5B | ||
| Q1 25 | $28.0B | $17.1B | ||
| Q4 24 | $28.0B | $16.9B | ||
| Q3 24 | $28.3B | $16.6B | ||
| Q2 24 | $26.8B | $15.4B | ||
| Q1 24 | $26.6B | $15.1B |
负债/权益比BIIBPR
| Q4 25 | 0.34× | 0.34× | ||
| Q3 25 | 0.35× | 0.35× | ||
| Q2 25 | 0.36× | 0.42× | ||
| Q1 25 | 0.27× | 0.43× | ||
| Q4 24 | 0.38× | 0.46× | ||
| Q3 24 | 0.28× | 0.47× | ||
| Q2 24 | 0.40× | 0.46× | ||
| Q1 24 | 0.41× | 0.56× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $511.9M | $904.3M |
| 自由现金流经营现金流 - 资本支出 | $468.0M | — |
| 自由现金流率自由现金流/营收 | 20.5% | — |
| 资本支出强度资本支出/营收 | 1.9% | — |
| 现金转化率经营现金流/净利润 | — | 2.66× |
| 过去12个月自由现金流最近4个季度 | $2.1B | — |
8季度趋势，按日历期对齐
经营现金流BIIBPR
| Q4 25 | $511.9M | $904.3M | ||
| Q3 25 | $1.3B | $766.5M | ||
| Q2 25 | $160.9M | $1.0B | ||
| Q1 25 | $259.3M | $898.0M | ||
| Q4 24 | $760.9M | $871.6M | ||
| Q3 24 | $935.6M | $954.4M | ||
| Q2 24 | $625.8M | $938.4M | ||
| Q1 24 | $553.2M | $647.6M |
自由现金流BIIBPR
| Q4 25 | $468.0M | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $134.3M | — | ||
| Q1 25 | $222.2M | — | ||
| Q4 24 | $721.6M | — | ||
| Q3 24 | $900.6M | — | ||
| Q2 24 | $592.3M | — | ||
| Q1 24 | $507.3M | — |
自由现金流率BIIBPR
| Q4 25 | 20.5% | — | ||
| Q3 25 | 48.4% | — | ||
| Q2 25 | 5.1% | — | ||
| Q1 25 | 9.1% | — | ||
| Q4 24 | 29.4% | — | ||
| Q3 24 | 36.5% | — | ||
| Q2 24 | 24.0% | — | ||
| Q1 24 | 22.1% | — |
资本支出强度BIIBPR
| Q4 25 | 1.9% | — | ||
| Q3 25 | 1.8% | — | ||
| Q2 25 | 1.0% | — | ||
| Q1 25 | 1.5% | — | ||
| Q4 24 | 1.6% | — | ||
| Q3 24 | 1.4% | — | ||
| Q2 24 | 1.4% | — | ||
| Q1 24 | 2.0% | — |
现金转化率BIIBPR
| Q4 25 | — | 2.66× | ||
| Q3 25 | 2.73× | 12.94× | ||
| Q2 25 | 0.25× | 5.01× | ||
| Q1 25 | 1.08× | 2.73× | ||
| Q4 24 | 2.85× | 4.02× | ||
| Q3 24 | 2.41× | 2.47× | ||
| Q2 24 | 1.07× | 3.99× | ||
| Q1 24 | 1.41× | 4.42× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BIIB
| Products | $1.7B | 73% |
| Tysabri Product | $244.5M | 11% |
| AVONEX | $119.2M | 5% |
| SKYCLARYS | $88.9M | 4% |
| Alzheimers Collaboration | $47.1M | 2% |
| IMRALDI | $43.5M | 2% |
| TECFIDERA | $36.9M | 2% |
| PLEGRIDY | $24.7M | 1% |
| QALSODY | $7.8M | 0% |
| BYOOVIZ | $4.3M | 0% |
PR
| Crude Oil | $1.0B | 87% |
| Natural Gas Liquids Reserves | $145.1M | 12% |
